Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$8.15
+0.9%
$8.01
$5.11
$10.67
$1.10B1.161.33 million shs1.49 million shs
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$10.18
+17.3%
$8.97
$6.11
$19.00
$813.82M1.9112,089 shs1.98 million shs
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
$15.73
-1.4%
$14.45
$8.24
$18.38
$1.03B-0.3487,257 shs946,814 shs
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$85.81
+0.1%
$83.59
$62.35
$90.04
$4.24B0.44297,868 shs296,398 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
+0.87%-1.81%-0.37%+2.52%+56.43%
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
+17.28%-10.70%+12.24%-11.56%-15.10%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-1.44%-2.30%+17.92%+62.50%+28.93%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
-0.20%-1.99%+6.56%-0.53%+34.13%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
3.0609 of 5 stars
3.51.00.00.04.11.71.9
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
0.3025 of 5 stars
0.02.00.00.02.41.70.0
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2.9279 of 5 stars
3.51.00.00.04.15.00.0
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
3.7426 of 5 stars
1.33.01.73.53.12.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
3.00
Buy$11.5041.10% Upside
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
3.00
BuyN/AN/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
3.00
Buy$38.00141.58% Upside
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
2.50
Moderate Buy$93.338.77% Upside

Current Analyst Ratings Breakdown

Latest PBH, AUPH, GYRE, and MLYS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$48.00
5/13/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
5/8/2025
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
4/2/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$30.00 ➝ $42.00
3/21/2025
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$96.00 ➝ $97.00
3/11/2025
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
Noble Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
3/10/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$247.30M4.45N/AN/A$2.63 per share3.10
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$100.64M9.48$0.20 per share50.49$0.18 per share56.56
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/A$3.84 per shareN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.14B3.73$5.04 per share17.03$36.10 per share2.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
-$78.02M$0.28N/A14.55N/A-10.23%-4.41%-3.07%8/7/2025 (Estimated)
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
-$92.93M$0.02509.00N/A-84.57%-118.43%-71.97%8/12/2025 (Estimated)
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$177.81M-$3.73N/AN/AN/AN/A-67.97%-62.40%8/12/2025 (Estimated)
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$209.34M$4.2920.0918.032.6919.13%12.36%6.39%8/14/2025 (Estimated)

Latest PBH, AUPH, GYRE, and MLYS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$0.08$0.16+$0.08$0.16$61.06 million$62.47 million
5/12/2025Q1 2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$1.02-$0.79+$0.23-$0.79N/AN/A
5/9/2025Q1 2025
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$0.03$0.03N/AN/A$28.40 million$22.06 million
5/8/2025Q4 2025
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.30$1.32+$0.02$1.00$289.36 million$296.52 million
3/17/2025Q4 2024
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$0.04$0.01-$0.03$0.02$23.50 million$27.87 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
N/AN/AN/AN/AN/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/AN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.902.21%N/A44.29%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
0.17
5.60
5.11
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
N/A
3.72
3.29
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/A
14.02
14.02
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
0.56
3.68
2.20

Institutional Ownership

CompanyInstitutional Ownership
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
36.83%
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
23.99%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
84.46%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
99.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
300135.10 million137.02 millionOptionable
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
4093.76 million75.27 millionNo Data
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2865.18 million33.27 millionOptionable
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
54049.42 million48.75 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.15 +0.07 (+0.87%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$8.36 +0.21 (+2.52%)
As of 08:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Gyre Therapeutics stock logo

Gyre Therapeutics NASDAQ:GYRE

$10.18 +1.50 (+17.28%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$10.20 +0.02 (+0.15%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Mineralys Therapeutics stock logo

Mineralys Therapeutics NASDAQ:MLYS

$15.73 -0.23 (-1.44%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$16.18 +0.45 (+2.89%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Prestige Consumer Healthcare stock logo

Prestige Consumer Healthcare NYSE:PBH

$85.80 +0.06 (+0.06%)
Closing price 05/27/2025 03:59 PM Eastern
Extended Trading
$85.87 +0.07 (+0.08%)
As of 05/27/2025 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.